The African Alliance

The African Alliance Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from The African Alliance, Non-Governmental Organization (NGO), Postnet Suite, Melville.

The Alliance works closely with a wide range of non-profit organisations in a network that, while rooted in the local, is connected to and visible in national, regional, and global actions, underpinned by a thoughtful, inclusive and consultative practice.

How concerned are you about AI's impact on your daily life, your data, your community?You're not alone. Based on our las...
25/08/2026

How concerned are you about AI's impact on your daily life, your data, your community?

You're not alone. Based on our last survey, 85.4% of you said yes: you want to be part of shaping the answer.

Africa's future shouldn't be decided without Africans.

If you haven't joined WATA yet, that's the invitation: a pan-African network of health activists, community organisers and AI thought leaders working to put community power back into how AI and data systems are governed.

It's free, and signing up takes less than 10 minutes. It's yours to shape.

Sign up in English, French or Kiswahili:

English: surveymonkey.com/r/HQGVMR9

Français: surveymonkey.com/r/WQSXPRT

Kiswahili: surveymonkey.com/r/WSTZ2HZ

Your data. Your community. Your voice.

Africa’s AI future shouldn’t be decided without Africans, and we’re building the platform to make sure it isn’t.We asked...
18/08/2026

Africa’s AI future shouldn’t be decided without Africans, and we’re building the platform to make sure it isn’t.

We asked communities across the continent what they think about AI, data and power. The message was clear:
79.1% say communities don’t have enough influence over AI decisions in their country.
58.1% have witnessed or experienced harm linked to AI or digital systems.

And when we asked if people wanted to do something about it: 85.4% said yes, they want to become WATA members.
So we’re bringing people together.

WATA (We Are The Algorithm) is a pan-African platform uniting health activists, community organisers and AI thought leaders to ensure that AI and data systems advance justice, dignity, rights and community power across Africa.

Our monthly WATA Gatherings are where that happens: a space to learn, to shape policy priorities, to organise, and to hold AI to account, together.
Membership is free and open to anyone living and working in Africa. Add your voice.

Sign up now in English, French and Kiswahili:

English: surveymonkey.com/r/HQGVMR9
Français: surveymonkey.com/r/WQSXPRT
Kiswahili: surveymonkey.com/r/WSTZ2HZ

Your data. Your community. Your voice.

It's all happening - your last chance to experience the Freedom Zone at !Drop by the Global Village to:✨ Chat with Amor...
30/07/2026

It's all happening - your last chance to experience the Freedom Zone at !

Drop by the Global Village to:

✨ Chat with Amor, our AI-powered inner condom companion.
✨ Watch live FC2 demonstrations from our incredible team.
✨ Discover our pan-African demand creation work helping expand informed choice for HIV prevention.
✨ Ask questions, explore resources, and connect with our team.

Whether you're a researcher, healthcare provider, advocate, or simply curious, we'd love to meet you. See you at the Global Village!

1/ Today at along with we presented our analysis of one of the most important HIV prevention breakthroughs of our gen...
29/07/2026

1/ Today at along with we presented our analysis of one of the most important HIV prevention breakthroughs of our generation - and one of its biggest ethical failures.

A Breakthrough Withheld: Power, Control and the Slow Rollout of Lenacapavir.

🧵👇

2/ Lenacapavir has the potential to transform HIV prevention.

But scientific innovation alone does not save lives.

Access does.

Our question was simple:

Has the rollout honoured the commitments made to the communities whose participation made this breakthrough possible?

3/ Our conclusion:

Not yet.

The evidence points to a managed retreat from the ambition that accompanied lenacapavir’s launch.

Promises of broad access have been replaced by cautious scarcity management

4/ The numbers tell the story.

• Licensing announced for 120 countries
• Initial focus on 18 priority countries
• By 2026, fewer than 12 countries had confirmed deliveries
• Available supply reaches only a tiny fraction of those who could benefit.

5/ In several countries, first-year supply represents less than 1% of estimated need.

A scientific breakthrough with global potential has begun with volumes too small to change the course of the epidemic.

6/ The language matters.

“Priority countries.”

“Phased rollout.”

“Early adopters.”

These terms can sound like orderly implementation.

In reality, they often describe the management of scarcity rather than equitable access.

7/ This is not simply a logistical problem.

It is an ethical one.

The communities that participated in research, carried the burden of HIV and contributed to scientific progress should not be the last to benefit at scale.

8/ Access cannot be an afterthought.

It must be designed before:
• clinical trials begin
• regulatory pathways are established
• commercial strategies are finalised.

Ethics must be built into product development- not retrofitted afterwards.

9/ We argue that governments, funders and manufacturers all have responsibilities.

Scientific success should be measured not only by efficacy in clinical trials, but by whether the people who need innovation can actually receive it.

10/ Our recommendations include:

✅ Expand non-exclusive licensing
✅ Commit to transparent supply allocations
✅ Establish enforceable delivery timelines
✅ Involve affected communities in access decisions
✅ Embed equitable access into future product development from day one.

11/ Lenacapavir has shown what science can achieve.

Now the challenge is whether politics, financing and intellectual property systems can match that achievement.

Without equitable access, innovation risks reinforcing the very inequalities it was meant to address.

12/ Thank you to our co-authors, in-country contributors and community partners across Africa and beyond whose evidence and lived experience informed this work.

The conversation doesn’t end with this presentation.

The next breakthrough must not be another breakthrough withheld.

1/ Today at along with presented our analysis of one of the most important HIV prevention breakthroughs of our genera...
29/07/2026

1/ Today at along with presented our analysis of one of the most important HIV prevention breakthroughs of our generation - and one of its biggest ethical failures.

A Breakthrough Withheld: Power, Control and the Slow Rollout of Lenacapavir.

🧵👇

2/ Lenacapavir has the potential to transform HIV prevention.

But scientific innovation alone does not save lives.

Access does.

Our question was simple:

Has the rollout honoured the commitments made to the communities whose participation made this breakthrough possible?

3/ Our conclusion:

Not yet.

The evidence points to a managed retreat from the ambition that accompanied lenacapavir’s launch.

Promises of broad access have been replaced by cautious scarcity management

4/ The numbers tell the story.

• Licensing announced for 120 countries
• Initial focus on 18 priority countries
• By 2026, fewer than 12 countries had confirmed deliveries
• Available supply reaches only a tiny fraction of those who could benefit.

5/ In several countries, first-year supply represents less than 1% of estimated need.

A scientific breakthrough with global potential has begun with volumes too small to change the course of the epidemic.

6/ The language matters.

“Priority countries.”

“Phased rollout.”

“Early adopters.”

These terms can sound like orderly implementation.

In reality, they often describe the management of scarcity rather than equitable access.

7/ This is not simply a logistical problem.

It is an ethical one.

The communities that participated in research, carried the burden of HIV and contributed to scientific progress should not be the last to benefit at scale.

8/ Access cannot be an afterthought.

It must be designed before:
• clinical trials begin
• regulatory pathways are established
• commercial strategies are finalised.

Ethics must be built into product development- not retrofitted afterwards.

9/ We argue that governments, funders and manufacturers all have responsibilities.

Scientific success should be measured not only by efficacy in clinical trials, but by whether the people who need innovation can actually receive it.

10/ Our recommendations include:

✅ Expand non-exclusive licensing
✅ Commit to transparent supply allocations
✅ Establish enforceable delivery timelines
✅ Involve affected communities in access decisions
✅ Embed equitable access into future product development from day one.

11/ Lenacapavir has shown what science can achieve.

Now the challenge is whether politics, financing and intellectual property systems can match that achievement.

Without equitable access, innovation risks reinforcing the very inequalities it was meant to address.

12/ Thank you to our co-authors, in-country contributors and community partners across Africa and beyond whose evidence and lived experience informed this work.

The conversation doesn’t end with this presentation.

The next breakthrough must not be another breakthrough withheld.

At ? Pass by our AI zone, learn all about inner condoms, win a year's supply of l**e, get updated on HIV Cure, get out...
27/07/2026

At ? Pass by our AI zone, learn all about inner condoms, win a year's supply of l**e, get updated on HIV Cure, get outraged at pharma dominance of HIV prevention decisions and more !
IAS - International AIDS Society

🔥 ARE YOU AFRICA’S NEXT HIV CURE MASTER TRAINER? 🔥The African Alliance, in partnership with the Africa HIV Cure Consorti...
30/01/2026

🔥 ARE YOU AFRICA’S NEXT HIV CURE MASTER TRAINER? 🔥

The African Alliance, in partnership with the Africa HIV Cure Consortium, is recruiting national trainers in Botswana, Kenya, South Africa, Uganda, and Zambia to roll out our HIV CUREiculum to other trainers.

We are building a small, high-quality pool of trainers who will be supported and paid to deliver Africa’s first community-led HIV cure training programme at the national and sub-national levels.

What’s involved
• Two-week, in-person Training-of-Trainers in March 2026
• Deliver 5 trainings in your country during 2026 - costs will be covered
• Work with communities, advocates, and national stakeholders shaping HIV cure research

Who should apply
- Be passionate about HIV in our lifetime
- Experienced trainers or facilitators (HIV, public health, research, rights, advocacy)
- Strong communicators who can translate complex ideas for real people
- Based in Botswana, Kenya, South Africa, Uganda, or Zambia

HIV cure expertise NOT required. Training experience IS required

Languages: English required. Swahili, French, or local languages are a plus.

📅 Deadline: 10 February 2026
📩 Questions: [email protected]

Link to application: https://lnkd.in/duRWbsiP









Address

Postnet Suite
Melville

Website

Alerts

Be the first to know and let us send you an email when The African Alliance posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to The African Alliance:

Shortcuts

Share

Category